Overview

CJC-1295 is a 29-amino acid synthetic analog of growth hormone-releasing hormone (GHRH), structurally based on the first 29 amino acids of native GHRH with four amino acid substitutions to improve stability, plus an attached Drug Affinity Complex (DAC) component. The DAC modification allows covalent binding to serum albumin, dramatically extending the half-life to several days and enabling sustained GH and IGF-1 elevation lasting up to 28 days after a single dose.

Mechanism of Action

CJC-1295 binds to GHRH receptors on pituitary somatotroph cells, activating G-proteins and downstream second messengers (cAMP, IP₃). This triggers protein kinase cascade activation and transcription factor phosphorylation, ultimately driving GH gene transcription and GH secretion. Studies indicate 2-10 fold increases in GH pulse amplitude and 1.5-3 fold increases in IGF-1 levels, with the DAC modification providing sustained albumin-bound reservoir activity.

Potential Benefits

  • 2-10 fold increase in growth hormone pulse amplitude
  • 1.5-3 fold increase in IGF-1 levels sustained for up to 28 days
  • Potential increase in lean muscle mass (~2.77 lbs over 16 weeks in early studies)
  • Improved fat metabolism and body composition
  • Enhanced recovery and repair processes
  • Anti-aging effects via GH/IGF-1 axis optimization
  • Prolonged half-life allowing less frequent dosing compared to native GHRH

Dosage Protocols

The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.

Typical Range100-300 mcg/dose, 1-3x/week
Beginner100 mcg 2x/week
Intermediate200 mcg 2-3x/week
Advanced300 mcg 3x/week
Cycle Duration8-12 weeks
Cycle Off4-8 weeks

CJC-1295 with DAC is typically dosed 1-2x/week due to extended half-life. Without DAC (Modified GRF 1-29), dose daily or before sleep. Combine with a GHRP for synergistic GH release (GHRH+GHRP is the gold standard stack).

Routes of Administration

Subcutaneous Injection High

Standard route; consistent absorption; inject into abdominal subcutaneous fat

Intramuscular Injection High

Faster peak but similar total exposure; less commonly used for CJC-1295

Stacking Protocols

Popular research stacks involving CJC-1295:

GH Optimization Stack

Maximized GH pulse amplitude with selective, clean release profile

The most popular GHRH+GHRP combination; CJC-1295 provides GH-releasing pulse amplitude while Ipamorelin selectively triggers release without cortisol/prolactin elevation.

Triple GH Stack

Aggressive GH stimulation for advanced users

Adding GHRP-2 further amplifies GH pulse; may increase appetite and slight cortisol elevation. For experienced users only.

Body Recomposition Stack

GH stimulation combined with targeted fat metabolism

AOD-9604 provides direct lipolytic activity while the GHRH/GHRP combination drives anabolic and recovery benefits.

Reconstitution

Typical Vial Size2mg, 5mg
BAC Water1-2ml per 2mg vial
StorageRefrigerate at 2-8°C after reconstitution
Shelf Life28 days refrigerated; stable lyophilized for 24+ months at -20°C

Need exact syringe measurements?

Amino Acid Sequence

Tyr-DAla-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Mpa)-NH2 (DAC conjugated)

Side Effects & Safety

  • Water retention and bloating
  • Increased hunger/appetite stimulation
  • Tingling or numbness in extremities
  • Potential insulin resistance with long-term use
  • Joint pain at high doses

Synergistic Compounds

The following compounds have been studied alongside CJC-1295 for potential complementary or synergistic effects:

Learn More

References & Further Reading

  • [object Object]
  • [object Object]